Business context and reporting period
Grifols, S.A. filed this IFRS annual report on Form 20-F for the fiscal year ended December 31, 2022—not a standalone Q4 report. It is a global plasma-derived medicines and diagnostics company; plasma-derived products accounted for most revenue. The 2022 results include Biotest from its April 25, 2022 acquisition. The financial statements received an unqualified audit opinion from KPMG.
Key financial metrics
| Metric | 2022 | 2021 | Change or context |
|---|---|---|---|
| Net revenue | €6,064.0 million | €4,933.1 million | +22.9% reported; +12.4% at constant currency |
| Gross profit / margin | €2,231.5 million / 36.8% | €1,962.6 million / 39.8% | Profit rose, but margin fell 3.0 percentage points |
| Operating result | €805.7 million | €595.1 million | +35.4% |
| Finance result | Loss of €442.9 million | Loss of €277.8 million | Higher interest rates and Biotest acquisition financing contributed |
| Profit before tax | €361.3 million | €350.5 million | +3.1% |
| Consolidated profit after tax | €271.1 million | €265.3 million | +2.2%; parent-attributable profit was €208.3 million versus €188.7 million |
| Basic and diluted EPS | €0.31 | €0.28 | Compared with €0.90 in 2020 |
| Operating cash flow | Outflow of €10.9 million | Inflow of €597.0 million | Primarily affected by working-capital use |
| Investing / financing cash flow | Outflow of €1,978.8 million / €173.5 million | Outflow of €854.1 million / inflow of €2,297.7 million | 2022 investing included the Biotest acquisition |
| Cash and cash equivalents | €548.0 million | €655.5 million | Year-end balance |
| Financial liabilities | €10,756.2 million | €10,207.2 million | €9,960.6 million was non-current at year-end |
Cost of sales was 63.2% of revenue versus 60.2% in 2021. Inventory rose €942.0 million to €3,201.4 million; the cash-flow statement attributes €600.2 million of operating working-capital use to inventory. Capital expenditure and additions to other intangible assets and rights of use totaled €542.7 million.
Material changes versus prior periods
- Biopharma revenue rose 31.2% reported (19.6% constant currency) to €5,005.4 million, supported by increased plasma collections, demand, pricing, Biotest and product mix. Immunoglobulin products represented approximately 43% of revenue versus 42% in 2021; Xembify sales increased 33.7%.
- Diagnostic revenue fell 13.8% reported (19.7% constant currency) to €671.3 million, mainly reflecting lower one-off COVID-19 test sales and the end of mandatory Zika testing.
- Revenue grew across reported regions: U.S. and Canada +22.2% (8.5% constant currency); EU +13.9% (13.5%); rest of world +34.9% (25.6%). Currency effects were material to reported growth.
- Plasma collections increased 25% in 2022 versus 2021 and exceeded 2019 levels. However, high donor compensation and labor costs, with an approximately nine-month inventory-cost lag, weighed on margins.
- Net revenue had declined 7.6% in 2021 versus 2020, and consolidated profit fell from €709.0 million in 2020 to €265.3 million in 2021 before edging up in 2022.
- Biotest acquisition-related financing and higher rates contributed to finance costs of €496.5 million, versus €278.0 million in 2021. The 2022 financial statements include €103.5 million of profit from equity-accounted investees with similar activity, versus €32.6 million in 2021.
Outlook, risks, contingencies and unusual items
- Outlook: The filing provides no clear 2023 revenue or earnings guidance. Management said it expects plasma collections to support 2023 needs and is targeting lower plasma costs and margin improvement.
- Cost plan: Announced in February 2023, the operational improvement plan targets approximately €100 million of income-statement savings in 2023 and approximately €400 million in annualized savings after full implementation, with most savings expected to be recognized in 2024. It includes about 2,000 U.S. plasma-operations positions and close to 300 corporate-function FTEs. A €140 million one-time restructuring charge was recorded on March 31, 2023.
- Liquidity and capital allocation: Management said cash, operating cash flow and available revolving credit were expected to cover obligations, working capital and capital expenditure for at least 12 months. The filing reports no 2022 dividend and says cash dividends are not expected until debt leverage is below 4.00:1.00. Debt covenants restrict dividends and other actions.
- Leverage and rates: Variable-rate debt exposes the company to rate increases; the filing estimates a 100-basis-point rise would increase annual interest expense by €34.7 million. It also identifies refinancing, covenant, collateral and subsidiary cash-distribution risks.
- Business risks: Key exposures include plasma availability and donor costs, manufacturing contamination or yield variation, regulatory compliance, product safety and liability, pricing and reimbursement pressure, competition, currency movements, cybersecurity, and execution of major capital projects. The U.S. dollar accounted for 73% of 2022 revenue.
- Contingencies and unusual matters: Grifols sought OFAC guidance or a license concerning Biotest’s pre-existing Iran-related plasma arrangements; it says termination would not materially affect operations or financial condition, but sanctions consequences remain uncertain. An Illinois biometric-privacy class action was settled for $16.75 million, subject to final court approval. A separate Abbott patent and royalty dispute remained unresolved; the filing also described a possible Siemens settlement, not a completed one.
- Controls and audit: Management and the auditor concluded internal control over financial reporting was effective at year-end; a prior material weakness concerning complex financial-instrument classification was reported as remediated. Biotest was excluded from management’s internal-control assessment following the acquisition. The auditor identified Diagnostic goodwill impairment and the Shanghai RAAS equity-method investment impairment as critical audit matters, citing sensitivity to forecast and valuation assumptions.
Important facts for investors to verify
- Reconcile reported revenue growth with constant-currency growth, acquisition contributions and segment performance.
- Assess whether plasma-cost reductions and the announced savings plan can restore gross margin, and verify realized savings against the €100 million and €400 million targets.
- Review operating cash generation, inventory levels and receivables, alongside debt maturities, interest-rate exposure, covenant headroom and available committed liquidity.
- Examine the carrying values and impairment assumptions for Diagnostic goodwill and the Shanghai RAAS investment, including the auditor’s sensitivity disclosures.
- Track final approval and funding of the Illinois settlement, developments in the OFAC matter and outcomes of the Abbott and Siemens disputes.
- Confirm the timing and conditions for any future dividend, given the stated leverage threshold, debt restrictions and Class B share preferences.